

Figure A.1. Survey design





Figure B.1. Difference in occurrence of side effects between currently using and discontinued group (%).



* indicates a significant difference ($p < 0.0017$, Fisher's Exact test) between the currently using and discontinued group

Figure C.1. Patient leaflet to inform patients what to expect when starting with pyridostigmine.


PYRIDOSTIGMINE

FOR THE TREATMENT OF MYASTHENIA GRAVIS

What to expect when starting?

TWO THIRDS of all patients continue using pyridostigmine


ONE THIRD of all patients discontinue pyridostigmine



EFFECTIVENESS

Most patients currently using pyridostigmine rate the effect with a score between **49 AND 81**.


No effect Full effect



DOSE

- Most patients use a dose between **180 AND 360 mg** per day.
- 95%** of all patients use a dose **LESS THAN 660 mg** per day.

REASONS FOR DISCONTINUING




Reason	Percentage
Not effective	~33%
Side effects too severe	~33%
No longer necessary	~20%
Other	~14%

FATIGUE

appears to be less responsive to pyridostigmine than other MG symptoms

MOST COMMON SIDE EFFECTS

- Flatulence
- Diarrhea
- Abdominal cramps
- Urinary urgency
- Muscle cramps
- Blurred vision
- Excessive sweating
- Increased salivation
- Light-headedness
- Flu-like symptoms



ALWAYS CONSULT YOUR NEUROLOGIST BEFORE MAKING ANY CHANGES TO YOUR MEDICATION.



Data are based on a cross-sectional study conducted in 410 patients with MG participating in the Dutch-Belgian MG Patient Registry

L. Remijn-Nelissen, J.J.G.M. Verschuuren, M.R. Tannemaat